Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib for Biliary Tract Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is testing olaparib to treat patients with biliary tract cancer that has spread and who have aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.